← Leaderboards
Eric J Sundberg
Emory University
$18,160,546
Attributed
$19,041,299
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,041,299 · 15
By mechanism
R01$16,765,937 · 8
R21$2,255,036 · 5
P41$13,326 · 1
R13$7,000 · 1
Top collaborators
- Blaine Russell Roberts2 shared
- Jeffrey Victor Ravetch1 shared
Most similar at Emory University
Same institution · by research overlap
- David Richard Myers$6,395,874
- Oluwamayokun Oshinowo$155,482
- Wilbur A Lam$39,688,140
- Frances Eun-Hyung Lee$16,287,959
- Cheryl Maier$1,473,950
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignMolecularStructureReceptorComplexBaseProteinsLinkPropertyEngineeringPolysaccharidesInflammatoryAffinityImmune ResponseHuman DiseaseImmune SystemAntibodiesSpecificityBindingMediatingCellsInfectionEventExhibits
Grant awards (52)
Engineering IgG-specific endoglycosidases to selectively defeat effector functions$663,219
R01 · FY2025 · AI · contact PI
Deciphering the IgG glycosylation code of Alzheimer's Disease$536,606
R01 · FY2025 · AG · contact PI
Gatekeeping glycan metabolism in the human gut microbiome$371,991
R01 · FY2025 · GM · contact PI
Deciphering the IgG glycosylation code of Alzheimer's Disease$561,681
R01 · FY2024 · AG · contact PI
Rationalizing glycoengineering strategies for immunotherapeutic antibodies$472,119
R01 · FY2024 · AI · contact PI
Gatekeeping glycan metabolism in the human gut microbiome$371,991
R01 · FY2024 · GM · contact PI
Engineering mono-fucosylated IgGs to fine-tune antibody-mediated effector functions$234,750
R21 · FY2024 · AI · contact PI
Gatekeeping glycan metabolism in the human gut microbiome$219,690
R01 · FY2024 · GM · contact PI
Microbial Glycobiology$7,000
R13 · FY2024 · AI · contact PI
Rationalizing glycoengineering strategies for immunotherapeutic antibodies$473,242
R01 · FY2023 · AI · contact PI
Gatekeeping glycan metabolism in the human gut microbiome$386,116
R01 · FY2023 · GM · contact PI
Engineering mono-fucosylated IgGs to fine-tune antibody-mediated effector functions$195,625
R21 · FY2023 · AI · contact PI
Rationalizing glycoengineering strategies for immunotherapeutic antibodies$471,202
R01 · FY2022 · AI · contact PI
Targeting EndoS to auto-antibodies$234,750
R21 · FY2022 · AI · contact PI
Engineering antibody effector functions by Glycan Remodeling Yeast Display$233,950
R21 · FY2022 · AI · contact PI
Rationalizing glycoengineering strategies for immunotherapeutic antibodies$472,242
R01 · FY2021 · AI · contact PI
Molecular mechanisms of IL-33 cytokine signaling$452,627
R01 · FY2021 · AI · contact PI
Towards one-step enzymatic defucosylation of antibodies$234,000
R21 · FY2021 · AI · contact PI
Engineering antibody effector functions by Glycan Remodeling Yeast Display$208,950
R21 · FY2021 · AI · contact PI
Targeting EndoS to auto-antibodies$195,261
R21 · FY2021 · AI · contact PI
Rationalizing glycoengineering strategies for immunotherapeutic antibodies$501,240
R01 · FY2020 · AI · contact PI
Molecular mechanisms of IL-33 cytokine signaling$471,202
R01 · FY2020 · AI · contact PI
Towards one-step enzymatic defucosylation of antibodies$195,000
R21 · FY2020 · AI · contact PI
Molecular mechanisms of IL-33 cytokine signaling$416,018
R01 · FY2019 · AI · contact PI
Structure & Function of Clostridium difficile Type IV Pili$379,009
R01 · FY2019 · AI · contact PI
Structure and Function of Clostridium difficile Type IV Pili$138,872
R01 · FY2019 · AI · contact PI
Molecular mechanisms of IL-33 cytokine signaling$125,190
R01 · FY2019 · AI · contact PI
Structure and Function of Clostridium difficile Type IV Pili$519,993
R01 · FY2018 · AI · contact PI
Molecular mechanisms of IL-33 cytokine signaling$491,934
R01 · FY2018 · AI · contact PI
Molecular mechanisms of IL-33 cytokine signaling$57,984
R01 · FY2018 · AI · contact PI
Structure and Function of Clostridium difficile Type IV Pili$519,993
R01 · FY2017 · AI · contact PI
Molecular mechanisms of IL-33 cytokine signaling$515,964
R01 · FY2017 · AI · contact PI
Structure and Function of Clostridium difficile Type IV Pili$519,993
R01 · FY2016 · AI · contact PI
Structure and Function of Clostridium difficile Type IV Pili$546,743
R01 · FY2015 · AI · contact PI
Molecular basis of myelomonocytic receptor function in HIV-1 infection$384,615
R01 · FY2014 · AI · contact PI
Molecular basis of ADCC-mediated HIV protection$493,696
R01 · FY2013 · AI · contact PI
Molecular basis of myelomonocytic receptor function in HIV-1 infection$361,538
R01 · FY2013 · AI · contact PI
Molecular basis of ADCC-mediated HIV protection$525,208
R01 · FY2012 · AI · contact PI
Molecular basis of myelomonocytic receptor function in HIV-1 infection$384,615
R01 · FY2012 · AI · contact PI
Molecular basis of ADCC-mediated HIV protection$560,677
R01 · FY2011 · AI · contact PI
Development of Superantigen Antagonists$367,538
R01 · FY2011 · AI · contact PI
Molecular basis of myelomonocytic receptor function in HIV-1 infection$242,675
R01 · FY2011 · AI · contact PI
Molecular basis of myelomonocytic receptor function in HIV-1 infection$186,600
R01 · FY2011 · AI · contact PI
Molecular basis of ADCC-mediated HIV protection$645,639
R01 · FY2010 · AI · contact PI
Molecular basis of myelomonocytic receptor function in HIV-1 infection$494,500
R01 · FY2010 · AI · contact PI
Development of Superantigen Antagonists$289,275
R01 · FY2010 · AI · contact PI
Development of Superantigen Antagonists$157,500
R01 · FY2010 · AI · contact PI
Development of Superantigen Antagonists$507,500
R01 · FY2009 · AI · contact PI
Development of Superantigen Antagonists$507,500
R01 · FY2008 · AI · contact PI
DEVELOPMENT OF SUPERANTIGEN ANTAGONISTS$13,326
P41 · FY2006 · RR · contact PI
Development of Superantigen Antagonists$300,000
R21 · FY2004 · AI
Development of Superantigen Antagonists$222,750
R21 · FY2003 · AI